Centers for Disease Control and Prevention - National Center for Health Statistics. Atrial Fibrillation. https://www.cdc.gov/heartdisease/atrial_fibrillation.htm. Published 2021. Accessed September 30, 2021.

Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–528.

Article  PubMed  Google Scholar 

Centers for Disease Control and Prevention - National Center for Health Statistics. About Multiple Cause of Death, 1999–2019. https://wonder.cdc.gov/mcd-icd10.html. Published 2019. Accessed Oct 14, 2021.

Chung MK, Eckhardt LL, Chen LY, et al. Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American Heart Association. Circulation. 2020;141(16):e750–72.

Article  PubMed  Google Scholar 

January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–51.

Article  PubMed  Google Scholar 

Hicks T, Stewart F, Eisinga A. NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis. Open Heart. 2016;3(1):e000279.

Article  PubMed  PubMed Central  Google Scholar 

Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712–23.

Article  CAS  PubMed  Google Scholar 

Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484–8.

Article  CAS  PubMed  Google Scholar 

Fradley MG, Beckie TM, Brown SA, et al. Recognition, prevention, and management of arrhythmias and autonomic disorders in cardio-oncology: a scientific statement from the American Heart Association. Circulation. 2021;144(3):e41–55.

Article  PubMed  PubMed Central  Google Scholar 

Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2020;42(5):373–498.

Article  Google Scholar 

Delluc A, Wang T-F, Yap E-S, et al. Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: guidance from the SSC of the ISTH. J Thromb Haemost. 2019;17(8):1247–52.

Article  PubMed  Google Scholar 

Sorigue M, Miljkovic MD. Atrial fibrillation and stroke risk in patients with cancer: a primer for oncologists. J Oncol Practice. 2019;15(12):641–50.

Article  Google Scholar 

Fradley MG, Ellenberg K, Alomar M, et al. Patterns of anticoagulation use in patients with cancer with atrial fibrillation and/or atrial flutter. JACC: CardioOncology. 2020;2(5):747–54.

PubMed  PubMed Central  Google Scholar 

Atterman A, Friberg L, Asplund K, Engdahl J. Net benefit of oral anticoagulants in patients with atrial fibrillation and active cancer: a nationwide cohort study. EP Europace. 2020;22(1):58–65.

PubMed  Google Scholar 

Malavasi VL, Fantecchi E, Gianolio L, et al. Atrial fibrillation in patients with active malignancy and use of anticoagulants: under-prescription but no adverse impact on all-cause mortality. Eur J Intern Med. 2019;59:27–33.

Article  PubMed  Google Scholar 

Chen ST, Hellkamp AS, Becker RC, et al. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. Eur Heart J Qual Care Clin Outcomes. 2019;5(2):145–52.

Article  PubMed  Google Scholar 

Melloni C, Dunning A, Granger CB, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial. Am J Med. 2017;130(12):1440-1448.e1441.

Article  CAS  PubMed  Google Scholar 

Fanola CL, Ruff CT, Murphy SA, et al. Efficacy and safety of Edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2018;7(16):e008987.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deng Y, Tong Y, Deng Y, Zou L, Li S, Chen H. Vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc. 2019;8(14):e012540.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sawant AC, Kumar A, McCray W, et al. Superior safety of direct oral anticoagulants compared to Warfarin in patients with atrial fibrillation and underlying cancer: a national veterans affairs database study. J Geriatr Cardiol. 2019;16(9):706–9.

PubMed  PubMed Central  Google Scholar 

Deitelzweig S, Keshishian AV, Zhang Y, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients with active cancer. JACC: CardioOncology. 2021;3(3):411–24.

PubMed  PubMed Central  Google Scholar 

Yasui T, Shioyama W, Oboshi M, Oka T, Fujita M. Oral anticoagulants in Japanese patients with atrial fibrillation and active cancer. Intern Med. 2019;58(13):1845–9.

Article  PubMed  PubMed Central  Google Scholar 

Ording AG, Horváth-Puhó E, Adelborg K, Pedersen L, Prandoni P, Sørensen HT. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. Cancer Med. 2017;6(6):1165–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ording AG, Søgaard M, Skjøth F, et al. Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants. Cancer Med. 2021;10(13):4405–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan Y-H, Chao T-F, Lee H-F, et al. Clinical outcomes in atrial fibrillation patients with a history of cancer treated with non-vitamin K antagonist oral anticoagulants. Stroke. 2021;52(10):3132–41.

Article  CAS  PubMed  Google Scholar 

Wu VC-C, Wang C-L, Huang Y-T, et al. Novel oral anticoagulant versus warfarin in cancer patients with atrial fibrillation: an 8-year population-based cohort study. J Cancer. 2020;11(1):92–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Atterman A, Friberg L, Asplund K, Engdahl J. Atrial fibrillation, oral anticoagulants, and concomitant active cancer: benefits and risks. TH Open. 2021;05(02):e176–82.

Article  Google Scholar 

Mehta HB, An H, Ardeshirrouhanifard S, Raji MA, Alexander GC, Segal JB. Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among adults with cancer and atrial fibrillation. Circ: Cardiovas Qual Outcomes. 2022;15(12):e008951.

Google Scholar 

Pastori D, Antonucci E, Violi F, et al. Thrombocytopenia and mortality risk in patients with atrial fibrillation: an analysis from the START Registry. J Am Heart Assoc. 2019;8(21):e012596.

Article  PubMed  PubMed Central  Google Scholar 

Labrecque JA, Swanson SA. Target trial emulation: teaching epidemiology and beyond. Eur J Epidemiol. 2017;32(6):473–5.

Article  PubMed  PubMed Central  Google Scholar 

Hernán MA, Wang W, Leaf DE. Target trial emulation: a framework for causal inference from observational data. JAMA. 2022;328(24):2446–7.

Article  PubMed  Google Scholar 

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806–8.

Article  Google Scholar 

Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758–64.

Article  PubMed  PubMed Central  Google Scholar 

Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70–5.

Article